NCT03424005.

Study name	A Phase Ib/II, Open‐Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy‐Based Treatment Combinations In Patients With Metastatic Triple‐Negative Breast Cancer (Morpheus‐TNBC)
Methods	A Phase Ib/II, Open‐Label, Multicenter, Randomized Umbrella Study
Participants	Patients With Metastatic Triple‐Negative Breast Cancer
Interventions	Atezolizumab + Chemo (Gemcitabine + Carboplatin or Eribulin) vs Capecitabine
Outcomes	OTRR. PFS. OS. Toxicity
Starting date	March 2018
Contact information	Study Director: Clinical Trials Hoffmann‐La Roche
Notes	Unclear whether platinum is randomised.